GTX-102 by Elleine Allapitan | Jul 5, 2023GTX-102 Summary: A phase 1/2 open-label, multiple-dose, dose-escalating clinical trial of the safety and tolerability of GTX-102 in pediatric patients with Angelman Syndrome...
Recent Comments